hF11

Fig1. Detection of F11 expression in liver by RT-PCR. 

Wild type: only one band at 364 bp with primers F1/R1(mF11);

Homozygous: only one band at 364 bp with primers F2/R2(hF11); 

Abbr. M, DNA marker; HO, homozygous; WT, wild type.

Fig 2. Detection of hF11 expression in plasma by ELISA (female，RayBiotech, ELH-CoagFXI-1). 

Abbr. HO, homozygous; WT, wild type.

Fig3. Detection of hF11 expression in plasma by ELISA (male，Abcam, ab108834). 

Abbr. HO, homozygous; WT, wild type.

Fig4. Prothrombinogen time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB) in hF11 mice. （male, A.  8-10 weeks of age; B. 10-12 weeks of age.)

Fig.5 Activated Partial Thromboplastin Time (APTT) of anti-human F11 antibody in hF11 mice. Compared with the PBS control group, Abelacimab treatment significantly prolonged APTT. At day 7 post-treatment, the degree of APTT prolongation was significantly greater in the high-dose group compared to the low-dose group. The hF11 mice were randomly divided into 3 groups (n=5 per group, 9 weeks old, male). Anti-human F11 antibody Abelacimab or PBS was administered via intravenous injection. Plasma samples for coagulation assessment were collected at pre-treatment (baseline), day 1, and day 7 following treatment. APTT was measured using citrated plasma samples according to standard protocol.